Purpose: The aim of this study was to compare the effects of risperidone long-acting injection (RLAI) and paliperidone palmitate (PP) on non-acute-phase social functioning in patients with schizophrenia. Patients and Methods: In this 6-month pilot, open-label, randomized controlled study, 30 patients with schizophrenia who had been treated with RLAI were randomly allocated to the RLAI continuation group or switched to the PP group. Patients were evaluated at baseline and 6 months with the Social Functioning Scale (SFS) as the primary outcome variable and University of California San Diego Performance-Based Skills Assessment Brief (UPSA-B), Social Emotional Cognition Task (SECT), Positive and Negative Syndrome Scale (PANSS), and Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) scores as secondary outcomes. Results: At baseline, the two groups did not significantly differ in demographic or clinical features. The two groups did not differ in total score changes for the UPSA-B, the SECT, the PANSS, and the DIEPSS. However, the total scores and the two subscales of the SFS, i.e. independence-competence and independence-performance, were more improved in the PP group compared to the RLAI group (total scores, p = 0.038; competence, p = 0.001, and performance, p = 0.007, respectively). Conclusion: These results suggest that PP may improve the total social functioning, independent life competence, and performance as compared to the RLAI group. However, these results are preliminary and need independent replication in larger samples before any definitive statement can be made.

Keywords:
Social functioning, Risperidone long-acting injection, Efficacy, Schizophrenia, Paliperidone palmitate
1.
Kane JM: Schizophrenia. N Engl J Med 1996;334:34-41.
2.
Whelden P, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429.
3.
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.
4.
Hansan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller H-J: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. 2. Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44.
5.
Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU: Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957-965.
6.
Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S: Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83-92.
7.
Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, An Der Heiden W, Nienhuis FJ, Walsh D: Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med 2000;30:1155-1167.
8.
Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, Harvey PD: Predicting schizophrenia patients' real world behavior with specific neuropsychological and functional capacity measure. Biol Psychiatry 2008;63:505-511.
9.
Twamley EW, Doshi RR, Nayak GV, Palmer BW, Golshan S, Heaton RK, Patterson TL, Jeste DV: Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am J Psychiatry 2002;159:2013-2020.
10.
Hooley JM: Social factors in schizophrenia. Curr Dir Psychol Sci 2010;19:238-242.
11.
Addington J, Addington D: Social and cognitive functioning in psychosis. Schizophr Res 2008;99:176-181.
12.
Barrio P, Batalla A, Castellvi P, Hidalgo D, Garcia M, Ortiz A, Grande I, Pons A, Parellada E: Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. Int Clin Psychopharmacol 2013;28:164-170.
13.
Harvey PD, Sabbag S, Prestia D, Durand D, Twamley EW, Patterson TL: Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J Psychiatr Res 2012;46:1546-1552.
14.
Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L: Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol 2014;29:45-55.
15.
Li H, Rui Q, Ning X, Xu H, Gu N: A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1002-1008.
16.
Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M: A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2012;15:107-118.
17.
Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G: A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-226.
18.
Gray JA, Roth BL: The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007;12:904-922.
19.
Drug Information for Paliperidone Palmitate: Interview Form of Xeplion® - Aqueous Suspension for IM Injection, ed 5. http://www.info.pmda.go.jp/go/pack/1179409G1025_1_07/. 2014.
20.
Matsuoka K, Uno M, Kasai K, Koyama K, Kim Y: Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of national adult reading test. Psychiatry Clin Neurosci 2006;60:332-339.
21.
Sumiyoshi C, Sumiyoshi T: Social Function Scale (MATRICS-PASS) - Japanese Version. Tokyo, 2011.
22.
Sumiyoshi C, Harvey PD, Takaki M, Okahisa Y, Sato T, Sora I, Nuechterlein KH, Subotnik KL, Sumiyoshi T: Factors predicting work outcome in Japanese patients with schizophrenia: role of multiple functioning levels. Schizophr Res Cogn 2015;2:105-112.
23.
Burns T, Patrick D: Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 2007;116:403-418.
24.
Mausbach BT, Depp CA, Bowie CR, Harvey PD, McGrath JA, Thronquist MH, Luke JR, Wolyniec PS, Pulver AE, Patterson TL: Sensitivity and specificity of the UCSD Performance-Based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. Schizophr Res 2011;132:165-170.
25.
Sumiyoshi T, Sumiyoshi C, Hemmi C: UCSD Performance-Based Skills Assessment-Brief (UPSA-B): Japanese Version - Administration and Scoring Manual. Tokyo, 2011, pp 1-14.
26.
Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ: A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 2009;31:848-859.
27.
Yoshida T, Suga M, Arima K, Muranaka Y, Tanaka T, Eguchi S, Lin C, Yoshida S, Ishikawa M, Higuchi Y, Seo T, Ueoka Y, Tomotake M, Kaneda Y, Darby D, Maruff P, Iyo M, Kasai K, Higuchi T, Sumiyoshi T, Ohmori T, Takahashi K, Hashimoto K: Criterion and construct validity of the CogState schizophrenia battery in Japanese patients with schizophrenia. PLoS One 2011;6:e20469.
28.
Pinkham AE, Sasson NJ, Calkins ME, Richard J, Hughett P, Gur RE, Gur RC: The other-race effect in face processing among African American and Caucasian individuals with schizophrenia. Am J Psychiatry 2008;165:639-645.
29.
Kay SR, Flszbeln A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
30.
Inada T: Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage. Tokyo, Seiwa Shoten, 1996.
31.
Nesvag R, Hendset M, Refsum H, Tanum L: Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006;114:21-26.
32.
Franberg O, Marcus MM, Svensson TH: Involvement of 5-HT2A receptor and alpha2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse 2012;66:650-660.
33.
Sara SJ: The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009;10:211-223.
34.
Nakagami E, Xie B, Hoe M, Brekke JS: Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr Res 2008;105:95-104.
35.
Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, Kim JM, Shin IS, Yoon JS: Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol 2012;27:267-274.
36.
Bandura A: Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977;84:191-215.
37.
Bandura A: Self-efficacy mechanism in human agency. Am Psychol 1982;37:122-147.
38.
Yamanashi S: The Investigation of Patients Questionnaire about Their Prescription - Comparison between Schizophrenia and Depression. Fukuoka, Zensei WEB bookstore, 2014.
39.
Pratt SI, Mueser KT, Smith TE, Lu W: Self-efficacy and psychosocial functioning in schizophrenia: a mediational analysis. Schizophr Res 2005;78:187-197.
40.
Morosini P-L, Magliano L, Brambilla L, Ugolini S, Pioli R: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;100:323-329.
41.
Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A: Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol 2013;23:1373-1382.
42.
Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, Losardo D, Lieberman JA: The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res 2009;115:17-23.
43.
Vazirani N: Review paper competencies and competency model-a brief overview of its development and application. J Manage 2010;7:121.
44.
Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW: Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-256.
45.
Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH: Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res 2009;113:189-199.
46.
Ciudad A, Olivares JM, Bousono M, Gomez JC, Alvarez E: Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1515-1522.
47.
Harvey PD, Velligan DI, Bellack AS: Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr Bull 2007;33:1138-1148.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.